Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
$0.00
$0.00
$0.01
$16K0.5342 shsN/A
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
$8.92
+1.1%
$7.52
$5.32
$11.64
$440.76M0.95793,813 shs348,531 shs
PetIQ, Inc. stock logo
PETQ
PetIQ
$30.98
$30.90
$15.09
$31.06
$925.99M1.73480,624 shsN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
0.00%0.00%+100.00%-50.00%-93.33%
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
0.00%+10.25%+13.20%+37.97%-18.69%
PetIQ, Inc. stock logo
PETQ
PetIQ
0.00%0.00%0.00%0.00%+37.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
3.7164 of 5 stars
1.05.01.71.42.83.31.3
PetIQ, Inc. stock logo
PETQ
PetIQ
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
0.00
N/AN/AN/A
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
2.00
Hold$6.88-22.93% Downside
PetIQ, Inc. stock logo
PETQ
PetIQ
2.00
Hold$31.000.06% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
N/AN/AN/AN/AN/AN/A
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
$1.73B0.25$2.25 per share3.97$13.10 per share0.68
PetIQ, Inc. stock logo
PETQ
PetIQ
$1.10B0.84$2.68 per share11.54$7.58 per share4.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
-$146.59M-$0.80N/A8.26N/A-2.30%6.99%3.25%8/6/2025 (Estimated)
PetIQ, Inc. stock logo
PETQ
PetIQ
$2.13M$0.3979.4424.59N/A1.20%18.75%5.15%N/A

Latest PETQ, BIOAF, and NUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
$0.15$0.23+$0.08$2.14$352.06 million$364.49 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
N/AN/AN/AN/AN/A
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
$0.242.69%N/AN/A N/A
PetIQ, Inc. stock logo
PETQ
PetIQ
N/AN/AN/AN/AN/A

Latest PETQ, BIOAF, and NUS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/9/2025
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
quarterly$0.063.5%5/30/20255/30/20256/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
N/AN/AN/A
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
0.29
2.02
1.29
PetIQ, Inc. stock logo
PETQ
PetIQ
1.68
2.58
1.68

Institutional Ownership

CompanyInstitutional Ownership
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
N/A
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
82.84%
PetIQ, Inc. stock logo
PETQ
PetIQ
94.99%

Insider Ownership

CompanyInsider Ownership
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
N/A
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
2.00%
PetIQ, Inc. stock logo
PETQ
PetIQ
9.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioasis Technologies Inc. stock logo
BIOAF
Bioasis Technologies
N/A79.41 millionN/ANot Optionable
Nu Skin Enterprises, Inc. stock logo
NUS
Nu Skin Enterprises
3,10049.41 million48.43 millionOptionable
PetIQ, Inc. stock logo
PETQ
PetIQ
1,93329.89 million27.01 millionOptionable

Recent News About These Companies

PetIQ Names Camillo Pane as Chief Executive Officer
PetIQ Acquired by Bansk Group, Delisted from Nasdaq
PetIQ announces completion of acquisition by Bansk Group
PetIQ Merges with Bansk Group in $1.5B Deal
PetIQ stockholders vote to approve merger agreement to be acquired by Bansk
PetIQ Inc Class A
The Return Trends At PetIQ (NASDAQ:PETQ) Look Promising
Should Value Investors Buy PetIQ (PETQ) Stock?
When Should You Buy PetIQ, Inc. (NASDAQ:PETQ)?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bioasis Technologies stock logo

Bioasis Technologies OTCMKTS:BIOAF

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

Nu Skin Enterprises stock logo

Nu Skin Enterprises NYSE:NUS

$8.92 +0.10 (+1.13%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$8.88 -0.04 (-0.45%)
As of 07/3/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

PetIQ stock logo

PetIQ NASDAQ:PETQ

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.